Gain Therapeutics, Inc. (GANX)

3.0000 -0.0300 (-0.99%) At close: 04:00PM EDT

Gain Therapeutics, Inc.

4800 Montgomery Lane
Suite 220
Bethesda, MD 20814
United States
301 500 1556
https://www.gaintherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Khalid Islam Ph.D.	Founder & Chairman	75k	N/A	1955
Mr. Matthias Alder LIC. IUR., LL.M.	President, CEO & Director	593k	N/A	1965
Mr. Gene Mack M.B.A.	Chief Financial Officer	N/A	N/A	N/A
Dr. Manolo Bellotto Ph.D.	GM & Chief Strategy Officer	251.99k	N/A	1971
Dr. Joanne Taylor Ph.D.	Senior Vice President of Research	N/A	N/A	N/A
Dr. Terenzio Ignoni Pharm.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Jonas Hannestad M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Corporate governance

Gain Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.